In Reply We sincerely thank Levy et al for their comments regarding radiotherapy in the setting of our phase 1 single-arm study of intratumoral (IT) TLR4 agonist injection with GLA-SE in metastatic sarcomas.¹ We value the authors’ questions about the radiotherapy doses and ranges delivered to the target lesions after IT GLA-SE. Although the authors are correct in identifying the protocol as dependent on the administrating radiation oncologist, the doses delivered were quite consistent. The median (range) dose delivered to all 12 patients was 3000 (2400-3500) cGy, and all were delivered in 5 fractions. Importantly, there was no apparent relationship between the dose of radiation delivered in the target lesion and the best local response.